首页 > 市场调查报告书 > 製药

生物标记

市场调查报告书

商品编码

1672193

全球 PARP 抑制剂生物标记市场研究报告 - 产业分析、规模、份额、成长、趋势和预测 2025 年至 2033 年

Global PARP Inhibitor Biomarkers Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

出版日期: 2025年03月01日 | 出版商:

Value Market Research | 英文 128 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球 PARP 抑制剂生物标记市场规模预计将从 2024 年的 10.1 亿美元成长到 2033 年的 22.3 亿美元，在 2026 年至 2033 年的预测期内呈现 9.11% 的强劲年复合成长率(CAGR)。

受癌症发病率上升和标靶治疗需求上升的推动，PARP 抑制剂生物标记市场正在经历显着增长。 PARP 抑制剂是一类在治疗具有特定基因突变的癌症（特别是乳癌和卵巢癌）方面显示出良好前景的药物。随着对癌症生物学理解的不断进步，识别和验证可预测 PARP 抑制剂反应的生物标记对于个人化医疗变得至关重要。随着研究人员和临床医生寻求优化治疗策略和改善患者治疗效果，预计市场将会扩大。

此外，生物标记发现技术的进步正在推动 PARP 抑制剂生物标记市场的创新。下一代定序、液体活检技术和生物资讯学工具的发展正在增强识别和验证与 PARP 抑制剂功效相关的生物标记的能力。这些创新不仅提高了生物标记检测的准确性，而且还促进了可指导治疗决策的伴随诊断的发展。随着研究不断探索新的生物标记及其临床应用，在癌症治疗精准度提高的推动下，市场可能会进一步扩大。

此外，对个人化医疗和以患者为中心的方法的日益重视正在塑造 PARP 抑制剂生物标记模式。随着医疗保健提供者越来越重视考虑个别患者特征的客製化治疗计划，对可以为治疗决策提供参考的可靠生物标记的需求可能会增加。这一趋势在临床试验和药物开发中尤其重要，其中生物标记驱动的策略可以提高新疗法的效率和成功率。随着 PARP 抑制剂生物标记市场不断发展，技术进步、个人化医疗的重点以及对有效癌症治疗的需求将在塑造其未来发展方面发挥关键作用。

我们的报告经过精心製作，为客户提供有关各个行业和市场的全面且可操作的见解。每份报告都包含几个关键部分，以确保彻底了解市场格局：

市场概览：市场的详细介绍，包括定义、分类和行业现状概述。

市场动态：深入分析影响市场成长的关键驱动因素、限制因素、机会与挑战。本节探讨技术进步、监管变化和新兴趋势等因素。

細項分析：根据产品类型、应用、最终用户和地理位置等标准将市场细分为不同的细分市场。该分析强调了每个部分的表现和潜力。

竞争格局：对主要市场参与者的全面评估，包括其市场份额、产品组合、策略倡议和财务表现。本节深入介绍领先公司的竞争动态和关键策略。

市场预测：根据历史资料和当前市场状况，预测特定时期内的市场规模和成长趋势。这包括定量分析和图形表示来说明未来的市场轨迹。

区域分析：评估不同地理区域的市场表现，确定关键市场和区域趋势。这有助于了解区域市场动态和机会。

新兴趋势与机会：识别当前和新兴的市场趋势、技术创新和潜在投资领域。本节提供未来市场发展和成长前景的见解。

区域展望
介绍
北美销售分析
- 概述、历史和预测数据销售分析
- 北美各细分市场销售分析
- 北美各国销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概述、历史和预测数据销售分析
- 欧洲各细分市场销售分析
- 欧洲各国销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概述、历史和预测数据销售分析
- 亚太地区分部销售分析
- 亚太地区国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概述、历史和预测数据销售分析
- 拉丁美洲各细分市场销售分析
- 拉丁美洲各国销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概述、历史和预测数据销售分析
- 中东和非洲分部销售分析
- 中东和非洲国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东和非洲其他地区销售分析

第 9 章：PARP 抑制剂生物标记公司的竞争格局

PARP 抑制剂生物标记市场竞争
伙伴关係/合作/协议
合併与收购
新产品发布
其他进展

第十章：公司简介

顶级公司市占率分析
市场集中度
Myriad Genetics Inc.

公司概况
公司收入
产品
最新动态

Ambry Genetics

公司概况
公司收入
产品
最新动态

Thermo Fisher Scientific Inc.

公司概况
公司收入
产品
最新动态

Illumina Inc.

公司概况
公司收入
产品
最新动态

Centogene NV

公司概况
公司收入
产品
最新动态

Amoy Diagnostics Co. Ltd.

公司概况
公司收入
产品
最新动态

Invitae Corporation

公司概况
公司收入
产品
最新动态

NeoGenomics Laboratories

公司概况
公司收入
产品
最新动态

QIAGEN

公司概况
公司收入
产品
最新动态

Agilent Technologies Inc

公司概况
公司收入
产品
最新动态

注意 - 在公司简介中，财务细节和最新发展取决于可用性，对于私人公司，可能不予涵盖

简介目录图表

Product Code: VMR112114327

Global PARP Inhibitor Biomarkers Market size is anticipated to grow from USD 1.01 Billion in 2024 to USD 2.23 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 9.11% during the forecast period of 2026 to 2033.

The PARP inhibitor biomarkers market is experiencing significant growth, driven by the increasing prevalence of cancer and the rising demand for targeted therapies. PARP inhibitors are a class of drugs that have shown promise in treating cancers with specific genetic mutations, particularly in breast and ovarian cancers. As the understanding of cancer biology advances, the identification and validation of biomarkers that predict response to PARP inhibitors are becoming critical for personalized medicine. This market is expected to expand as researchers and clinicians seek to optimize treatment strategies and improve patient outcomes.

Moreover, advancements in biomarker discovery technologies are propelling innovation within the PARP inhibitor biomarkers market. The development of next-generation sequencing, liquid biopsy techniques, and bioinformatics tools is enhancing the ability to identify and validate biomarkers associated with PARP inhibitor efficacy. These innovations not only improve the accuracy of biomarker testing but also facilitate the development of companion diagnostics that can guide treatment decisions. As research continues to explore new biomarkers and their clinical applications, the market is likely to expand further, driven by the promise of improved precision in cancer therapy.

Additionally, the growing emphasis on personalized medicine and patient-centric approaches is shaping the PARP inhibitor biomarkers landscape. As healthcare providers increasingly prioritize tailored treatment plans that consider individual patient characteristics, the demand for reliable biomarkers that can inform treatment decisions is likely to increase. This trend is particularly relevant in the context of clinical trials and drug development, where biomarker-driven strategies can enhance the efficiency and success rates of new therapies. As the PARP inhibitor biomarkers market continues to evolve, the combination of technological advancements, a focus on personalized medicine, and the need for effective cancer treatments will play a crucial role in shaping its future trajectory.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Product

Kits
Assays

By Services

BRCA 1 & 2 Testing
HRD Testing
HRR Testing
Others

By Application

Breast Cancer
Ovarian Cancer
Others
COMPANIES PROFILED
Myriad Genetics Inc.
Ambry Genetics
Thermo Fisher Scientific Inc.
Illumina Inc.
Centogene N.V.
Amoy Diagnostics Co. Ltd.
Invitae Corporation
NeoGenomics Laboratories
QIAGEN
Agilent Technologies Inc.
The above list can be customized.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. PARP INHIBITOR BIOMARKERS INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porters Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product
- 3.7.2 Market Attractiveness Analysis By Services
- 3.7.3 Market Attractiveness Analysis By Application
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL PARP INHIBITOR BIOMARKERS MARKET ANALYSIS BY PRODUCT

5.1. Overview By Product
5.2. Historical and Forecast Data Analysis By Product
5.3. Kits Historic and Forecast Sales By Regions
5.4. Assays Historic and Forecast Sales By Regions

6. GLOBAL PARP INHIBITOR BIOMARKERS MARKET ANALYSIS BY SERVICES

6.1. Overview By Services
6.2. Historical and Forecast Data Analysis By Services
6.3. BRCA 1 & 2 Testing Historic and Forecast Sales By Regions
6.4. HRD Testing Historic and Forecast Sales By Regions
6.5. HRR Testing Historic and Forecast Sales By Regions
6.6. Others Historic and Forecast Sales By Regions

7. GLOBAL PARP INHIBITOR BIOMARKERS MARKET ANALYSIS BY APPLICATION

7.1. Overview By Application
7.2. Historical and Forecast Data Analysis By Application
7.3. Breast Cancer Historic and Forecast Sales By Regions
7.4. Ovarian Cancer Historic and Forecast Sales By Regions
7.5. Others Historic and Forecast Sales By Regions

8. GLOBAL PARP INHIBITOR BIOMARKERS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE PARP INHIBITOR BIOMARKERS COMPANIES

9.1. PARP Inhibitor Biomarkers Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF PARP INHIBITOR BIOMARKERS INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Myriad Genetics Inc.
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Ambry Genetics
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Thermo Fisher Scientific Inc.
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Illumina Inc.
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Centogene N.V.
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Amoy Diagnostics Co. Ltd.
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Invitae Corporation
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. NeoGenomics Laboratories
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. QIAGEN
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Agilent Technologies Inc
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

简介目录图表

LIST OF TABLES

Market Snapshot
Drivers: Impact Analysis
Restraints: Impact Analysis
List of Raw Material
List of Raw Material Manufactures
Analysis By Product (USD MN)
Kits Market Sales By Geography (USD MN)
Assays Market Sales By Geography (USD MN)
Analysis By Services (USD MN)
BRCA 1 & 2 Testing Market Sales By Geography (USD MN)
HRD Testing Market Sales By Geography (USD MN)
HRR Testing Market Sales By Geography (USD MN)
Others Market Sales By Geography (USD MN)
Analysis By Application (USD MN)
Breast Cancer Market Sales By Geography (USD MN)
Ovarian Cancer Market Sales By Geography (USD MN)
Others Market Sales By Geography (USD MN)
Global PARP Inhibitor Biomarkers Market Sales By Geography (USD MN)
North America Market Analysis (USD MN)
United States Market Analysis (USD MN)
Canada Market Analysis (USD MN)
Mexico Market Analysis (USD MN)
Europe Market Analysis (USD MN)
Europe Market Estimate By Country (USD MN)
United Kingdom Market Analysis (USD MN)
France Market Analysis (USD MN)
Germany Market Analysis (USD MN)
Italy Market Analysis (USD MN)
Russia Market Analysis (USD MN)
Spain Market Analysis (USD MN)
Rest of Europe Market Analysis (USD MN)
Asia Pacific Market Analysis (USD MN)
China Market Analysis (USD MN)
Japan Market Analysis (USD MN)
India Market Analysis (USD MN)
South Korea Market Analysis (USD MN)
Australia Market Analysis (USD MN)
South East Asia Market Analysis (USD MN)
Rest of Asia Pacific Market Analysis (USD MN)
Latin America Market Analysis (USD MN)
Brazil Market Analysis (USD MN)
Argentina Market Analysis (USD MN)
Peru Market Analysis (USD MN)
Chile Market Analysis (USD MN)
Rest of Latin America Market Analysis (USD MN)
Middle East & Africa Market Analysis (USD MN)
Saudi Arabia Market Analysis (USD MN)
UAE Market Analysis (USD MN)
Israel Market Analysis (USD MN)
South Africa Market Analysis (USD MN)
Rest of Middle East and Africa Market Analysis (USD MN)
Partnership/Collaboration/Agreement
Mergers And Acquisition

LIST OF FIGURES

Research Scope of PARP Inhibitor Biomarkers Report
Market Research Process
Market Research Methodology
Global PARP Inhibitor Biomarkers Market Size, By Region (USD MN)
Porters Five Forces Analysis
Market Attractiveness Analysis By Product
Market Attractiveness Analysis By Services
Market Attractiveness Analysis By Application
Market Attractiveness Analysis By Region
Value Chain Analysis
Global Market Analysis By Product (USD MN)
Kits Market Sales By Geography (USD MN)
Assays Market Sales By Geography (USD MN)
Global Market Analysis By Services (USD MN)
BRCA 1 & 2 Testing Market Sales By Geography (USD MN)
HRD Testing Market Sales By Geography (USD MN)
HRR Testing Market Sales By Geography (USD MN)
Others Market Sales By Geography (USD MN)
Global Market Analysis By Application (USD MN)
Breast Cancer Market Sales By Geography (USD MN)
Ovarian Cancer Market Sales By Geography (USD MN)
Others Market Sales By Geography (USD MN)
Global Market Sales (USD MN)
North America Market Sales (USD MN)
Europe Market Sales (USD MN)
Asia Pacific Market Sales (USD MN)
Latin America Market Sales (USD MN)
Middle East & Africa Market Sales (USD MN)
Recent Development in Industry
Top Company Market Share Analysis
Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.